PORTLAND, Ore. , April 28, 2015 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced that

PORTLAND, Ore. , March 19, 2015 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced

- Basic tests for diseases of the arteries, lungs, eyes, nerves and heart -

Annual Growth of 60% and Quarterly Sequential Growth of 18% Reported

Year Over Year Revenue Growth of 93%; Quarterly Sequential Growth of 88%

Improvement in Operating Expenses Supports Goal of Profitability in 2016

-Semler builds momentum with revenue up 95% year-over-year and strengthens balance sheet with IPO proceeds-

Period over Period Growth of 44%; Quarterly Sequential Growth of 14%

Inventory and Manufacturing Capacity Grow to Prepare for Larger Orders

Profitability Continues SAN JOSE, Calif. , May 1, 2018 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three